Conshohocken-based Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company, recently announced that Bill Sibold is its new CEO.
Sibold also joined the company’s board of directors.
“We have a unique opportunity to build on the company’s legacy of scientific innovation, strengthen our partnerships with the healthcare community, and most importantly deliver a first-in-class, transformational therapy for patients with NASH (nonalcoholic steatohepatitis),” Sibold said. “It is a great honor to join a company that is taking on a significant unmet need in medicine today, and I look forward to working with our executive team and our employees to write the next chapter of the Madrigal story together.”
The company recently requested a priority U.S. Food and Drug Administration review for resmetirom, a drug for the treatment of NASH with liver fibrosis.
Sibold holds degrees in molecular biophysics and biochemistry. Prior to Madrigal, Sibold worked for Sanofi Genzyme. He joined the company as global franchise head for multiple sclerosis, oncology and immunology. He later served as executive vice president of specialty care and was a member of the Sanofi Executive Committee.
He also served as Avanir Pharmaceuticals chief commercial officer, and Lycera Corp. president and CEO.
Sibold succeeded Dr. Paul Friedman who will continue to serve on the board of directors.